30. Did the quantities of resources used seem appropriate? 31. What sources were used to value resource use and how appropriate were these? Time factors 32. Were costs and benefits discounted at the rate specified in SMC guidance? 33. Were costs indexed to the current year? If not, to what extent is this likely to bias the results? Summary 34. Overall, what were the key strengths and weaknesses in the handling of resource use and costs? If there were weaknesses, what difference is this likely to have made to the results of the economic evaluation? Analysis of Results Baseline result 35. What were the main economic results (e.g. net cost per QALY gained)? 36. Were results reported for different sub-groups of patients? If so, what were these? If the submitting company has requested the medicine be assessed under the End of Life/ Orphan medicines process, comment specifically on whether there any subgroups in which treatment may be more cost-effective and the robustness of the evidence base for these groups. Sensitivity analysis 37. What type(s) of sensitivity analysis was performed and what were the main findings reported? 38. Did it identify all the variables that the results are sensitive to?
30. Did the quantities of resources used seem appropriate? 31. What sources were used to value resource use and how appropriate were these? Time factors 32. Were costs and benefits discounted at the rate specified in SMC guidance? 33. Were costs indexed to the current year? If not, to what extent is this likely to bias the results? Summary 34. Overall, what were the key strengths and weaknesses in the handling of resource use and costs? If there were weaknesses, what difference is this likely to have made to the results of the economic evaluation? Analysis of Results Baseline result 35. What were the main economic results (e.g. net cost per QALY gained)? 36. Were results reported for different sub-groups of patients? If so, what were these? If the submitting company has requested the medicine be assessed under the End of Life/ Orphan medicines process, comment specifically on whether there any subgroups in which treatment may be more cost-effective and the robustness of the evidence base for these groups. Sensitivity analysis 37. What type(s) of sensitivity analysis was performed and what were the main findings reported? 38. Did it identify all the variables that the results are sensitive to?